Pablo Legorreta, chief executive and founder of Royalty Pharma

Pablo Legorreta is down but not out. The man behind the high profile and often crabby campaign to acquire Ireland’s largest indigenous pharma group El(...)

Elan chairman Robert Ingram. In a statement to the Irish Stock Exchange, Elan said it was “proceeding with a formal sale process”. Photograph: David Sleator

Irish biotech group Elan has put itself on the market after indications that shareholders will reject key elements of its restructuring plan.In a stat(...)

The idea started when Pablo Legorreta came across an innovative scheme pioneered by Paine Webber bankers.

It may be Dublin-based, but Royalty Pharma was unknown even here until it announced its interest in acquiring Elan, Ireland’s largest indigenous pharm(...)

Royalty Pharma has reduced the acceptance threshold for its increased $6.4 billion bid for Elan to 50 percent plus one share. Photograph: John Cogill/Bloomberg.

Royalty Pharma has reduced the acceptance threshold for its increased $6.4 billion bid for Elan to 50 per cent plus one share as it sought to(...)

Elan chief executive Kelly Martin, chairman Robert A Ingram, and company secretary Liam Daniel. Photograph: Cyril Byrne

Elan considered buying US investment firm Royalty Pharma last year, six months before Royalty made its approach for the Irish drugmaker, the of(...)